Adocia SA, also known as Adocia, is a France-based company engaged in the biotechnology business sector. It specializes in the research and development of biotherapy products used in tissue regeneration and for treating chronic diseases. The Company develops a BioChaperone Platform used for therapeutic protein delivery in regenerative medicine and chronic disease areas, such as wound Healing, diabetes, ulcers and monoclonal antibody creation. The Company completed two Phases I and II studies of the formulation of human insulin, two Phases I and II studies of insulin lispro and one Phase I/II on a combination of insulin glargine, the basal insulin and insulin lispro, an insulin analog. Adocia also undertaken the activities in the field of formulation of monoclonal antibodies which are molecules for the treatment of various chronic pathologies (oncology, inflammation, etc.).